The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Hepion Pharmaceuticals, Inc. listata cu simbolurile US.HEPA, US.HEPAc ==Descriere companie== Hepion Pharmaceuticals, Inc.(https://hepionpharma.com/) is a clinical stage biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Hepion Pharmaceuticals, Inc.(https://hepionpharma.com/) is a clinical stage biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. | Hepion Pharmaceuticals, Inc.(https://hepionpharma.com/) is a clinical stage biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company’s cyclophilin inhibitor, CRV431, offer benefits to address these multiple complex pathologies. CRV431 is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company has created an AI platform, called AI-POWR, which stands for Artificial Intelligence Precision Medicine Omics World database access and Response and clinical outcomes. The platform helps to identify which NASH patients will [[BEST|best]] respond to CRV431, potentially shortening development timelines and increasing the [[DELTA|delta]] between placebo and treatment groups. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||